Mouwasat Medical Services Company (4002) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2025 reached SR 1.56 billion, up from SR 1.41 billion year-over-year, driven by growth in both medical services and pharmaceutical sales.

• Net profit attributable to shareholders for the six-month period was SR 384.0 million, compared to SR 324.3 million for the same period last year.

• The interim financial statements received an unqualified review conclusion from the independent auditor.

Financial highlights

• Gross profit for the six months was SR 703.6 million, up from SR 653.3 million year-over-year.

• Basic and diluted EPS for the six months was SR 1.92, compared to SR 1.62 for the prior year period.

• Total assets as of 30 June 2025 stood at SR 5.55 billion, up from SR 5.40 billion at year-end 2024.

• Cash and cash equivalents at period end were SR 326.2 million, down from SR 426.6 million at year-end 2024.

• Dividends of SR 400 million were paid during the period.

Outlook and guidance

• The company continues to invest in expansion projects, with capital commitments of SR 296.1 million as of 30 June 2025.

• Management expects no material impact from forthcoming accounting standards.